Arrowhead Research | ARWR - Capital Social Ordinario





Capital Social Ordinario Cambio Fecha
Agios Pharmaceuticals USD 59.34M 892K 2026-03
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 137.39M 1.69M 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 12.72M 2025-12
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Novartis USD 1.91B 60K 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
TG Therapeutics USD 155.31M 95K 2025-12
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xencor USD 74.06M 2.19M 2026-03